Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab.
Herbert
Kirsten E
KE
Prince
H Miles
HM
Westerman
David A
DA
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000628:therapy; D009894:Opportunistic Infections / Q000821:virology; D010322:Parvoviridae Infections / Q000209:etiology*; D016732:Parvovirus B19, Human; D012010:Red-Cell Aplasia, Pure / Q000821:virology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab